Sapphire 3 CTO Study
NCT06358508
- Conditions
- Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Cardiovascular Diseases, Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery
- Interventions
- Sapphire 3 Coronary Dilatation Catheter
- Device
- Lead sponsor
- OrbusNeich
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 12
- States / cities
- Stanford, California • Torrance, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 22, 2026, 4:08 AM EDT